1 active not recruiting, 1 not yet recruiting. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Active not recruiting 1, Not yet recruiting 1 |
Follow PF-07220060: new trials by email Literature Review of PF-07220060 trials Research Report on PF-07220060
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Medicine Called Atirmociclib in Combination With Giredestrant in Adult Participants With ER-positive, HER2-negative Early-stage Breast Cancer Atirmociclib, giredestrant, Atirmociclib placebo - Early Breast Cancer, Estrogen Receptor Positive (ER+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) | Phase 3 | Not yet recruiting | Pfizer | 3800 | 2026-12-01 | 2026-10-22 |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease PF-07220060, letrozole, abemaciclib - Breast Cancer | Phase 3 | Active not recruiting | Pfizer | 1035 | 2025-01-06 | 2026-10-16 |
Breast Neoplasms (2) · Recurrence (1) · Unilateral Breast Neoplasms (1)
Pfizer (2)
Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Canada (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Germany (1) · Greece (1) · Hungary (1) · India (1)